{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"76","upperLimit":"95","value":"88"},{"groupId":"OG001","lowerLimit":"69","upperLimit":"92","value":"83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"description":"Percentage of participants with PR or better to treatment per the International Uniform Response Criteria for Multiple Myeloma stringent Complete Response- CR criteria + normal serum free light chain (FLC) ratio + absence of clonal cells in bone marrow (BM) by immunohistochemistry or immunofluorescence CR- Negative immunofixation (IFX) on serum \\& urine M proteins + \\<5% plasma cells in BM + disappearance of soft tissue plasmocytomas (STP) very good PR- PR criteria + serum \\& urine M proteins detectable by IFX but not on electrophoresis or \\>=90% reduction (RED) in serum M protein \\& urine M protein \\<100 g/24 hrs PR- \\>=50% RED in size of STP, if present at baseline \\& \\>=50% RED in plasma cells, if \\>=30% plasma cells in BM at baseline: \\& RED in serum M protein of \\>=50% \\& in urine M protein of \\>= 90% or to 200 mg/24hr OR if serum M protein \\<1 g/dL, urine M protein \\<200 mg/24 hrs, \\& involved serum FLC level \\>= 10 mg/dl at baseline: \\>= 50% RED in (involved-uninvolved) serum FLC levels","dispersionType":"95% Confidence Interval","groups":[{"description":"INDUCTION: Participants receive bortezomib SC or IV on days 1, 4, 8, and 11; lenalidomide PO QD on days 1-14; and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity (participants who received a course of chemotherapy prior to registration will begin protocol treatment with course 2 and receive a total of 7 courses of protocol therapy).\n\nMAINTENANCE: Participants receive bortezomib SC or IV on days 1, 8, and 15; lenalidomide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nBortezomib: Given SC or IV\n\nDexamethasone: Given PO or IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO","id":"OG000","title":"Arm I (Bortezomib, Lenalidomide, Dexamethasone)"},{"description":"INDUCTION: Participants receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Participants also receive elotuzumab IV on days 1, 8, and 15 of courses 1 and 2 and on days 1 and 11 of courses 3-8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE:Participants receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Participants also receive elotuzumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nBortezomib: Given SC or IV\n\nDexamethasone: Given PO or IV\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO","id":"OG001","title":"Arm II (Bortezomib, Lenalidomide, Dexamethasone, Elotuzumab)"}],"paramType":"NUMBER","populationDescription":"Eligible participants assessable for response at follow up. 1 participant on Arm II was not assessable for RR.","reportingStatus":"POSTED","timeFrame":"Up to 6 years post registration","title":"Response (Partial Response [PR] or Better) Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}